Minerva Biotechnologies Corporation

20 articles about Minerva Biotechnologies Corporation

• Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor Cancers

  1/9/2023

  Minerva Biotechnologies, a private company developing 1st-in-human therapies for the treatment of solid tumor cancers, announced today that the FDA has approved their IND (Investigational New Drug) application to conduct clinical trials with huMNC2-CAR22, aka MUC1*-CAR-1XX, for the treatment of metastatic breast cancers.

• Minerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Technology

  6/22/2020

  Minerva Biotechnologies (Minerva) today announced that it has licensed from Memorial Sloan Kettering Cancer Center (MSK) “1XX” technology for use with Minerva’s proprietary anti-MUC1* antibodies to increase CAR T cell persistence in patients. “This promises to be a great step forward for CAR T cell treatment of solid tumors,” said Minerva CEO Dr. Cynthia Bamdad. “We are combining Minerva’s demonstrated cancer-specific

• Minerva Biotechnologies Announces FDA Acceptance of IND Application for huMNC2-CAR44 T cells to Treat Metastatic Breast Cancer

  6/24/2019

  Unlike the normal full-length MUC1, MUC1* is a potent growth factor receptor that is rendered constitutively active when onco-embryonic growth factor NME7AB binds to and dimerizes its truncated extracellular domain.

• ACEA Biosciences Hosted Cancer and Immunotherapy Symposium for Leading Scientists in T Cell Therapy

  5/3/2018

  ACEA Biosciences, a biotechnology company that develops high performance cell analysis instruments, hosted their 6th annual Cancer Immunotherapy Symposium focused on CAR-T cell and TCR therapy on April 14, 2018 at the W Hotel in Chicago, prior to the 2018 AACR Annual Meeting.

• Minerva Biotechnologies Announces CellSystems as European Distributor of AlphaSTEM™, Naïve Stem Cell Culture System

  2/26/2018

  Minerva Biotechnologies Corporation, a leading cancer immunotherapy and regenerative medicine company, announces European distribution agreement with CellSystems Biotechnologie Vertrieb a major European life science supplier, for AlphaSTEM™ Naïve Stem Cell Culture System.

• Minerva Biotechnologies Corporation Announces Outcome Of End-Of-Phase II Meeting With FDA

  5/15/2017

• Minerva Biotechnologies Corporation Launches AlphaSTEM, A Naïve Stem Cell Culture System

  2/14/2017

• Minerva Biotechnologies Corporation Discovers Naïve Stem Cell Growth Factor

  2/17/2016

• Minerva Biotechnologies Corporation Licenses Sendai Virus Technology for Stem Cell Generation

  8/27/2015

• Minerva Biotechnologies Corporation Granted Worldwide License to iPS Technology

  8/4/2015

• Minerva Biotechnologies Corporation to Give Company Presentation at 2013 Stem Cell Meeting on the Mesa

  10/14/2013

• Minerva Biotechnologies Corporation to Give Company Presentation at 2013 Stem Cell Meeting on the Mesa

  10/11/2013

• Minerva Biotechnologies Corporation Announces Major Breakthrough in Human Stem Cell Research

  3/8/2013

• Minerva Biotechnologies Corporation Raises $4.6 Million

  11/18/2010

• Minerva Biotechnologies Corporation Awarded Grant Under the Patient Protection and Affordable Care Act

  11/5/2010

• Clarient, Inc. Granted Exclusive License to Commercialize Cancer Biomarker by Minerva Biotechnologies Corporation Biomarker Identifying MUC1* Protein May Be Key to Treatment of Variety of Cancers

  11/30/2009

• Minerva Biotechnologies Corporation's MUC1* Inhibitors Reverse Resistance to Chemotherapy

  5/12/2009

• Minerva Biotechnologies Corporation Announces Major Stem Cell Breakthrough

  10/3/2008

• Minerva Biotechnologies Corporation Settles Litigation

  9/4/2008

• Minerva Biotechnologies Corporation Looks for New CEO

  2/1/2008